164 related articles for article (PubMed ID: 24249805)
1. Conclusions and future directions for the REiNS International Collaboration.
Widemann BC; Blakeley JO; Dombi E; Fisher MJ; Hanemann CO; Walsh KS; Wolters PL; Plotkin SR
Neurology; 2013 Nov; 81(21 Suppl 1):S41-4. PubMed ID: 24249805
[TBL] [Abstract][Full Text] [Related]
2. Achieving consensus for clinical trials: the REiNS International Collaboration.
Plotkin SR; Blakeley JO; Dombi E; Fisher MJ; Hanemann CO; Walsh KS; Wolters PL; Widemann BC
Neurology; 2013 Nov; 81(21 Suppl 1):S1-5. PubMed ID: 24249801
[TBL] [Abstract][Full Text] [Related]
3. Recommendations for imaging tumor response in neurofibromatosis clinical trials.
Dombi E; Ardern-Holmes SL; Babovic-Vuksanovic D; Barker FG; Connor S; Evans DG; Fisher MJ; Goutagny S; Harris GJ; Jaramillo D; Karajannis MA; Korf BR; Mautner V; Plotkin SR; Poussaint TY; Robertson K; Shih CS; Widemann BC;
Neurology; 2013 Nov; 81(21 Suppl 1):S33-40. PubMed ID: 24249804
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials.
Wolters PL; Martin S; Merker VL; Gardner KL; Hingtgen CM; Tonsgard JH; Schorry EK; Baldwin A;
Neurology; 2013 Nov; 81(21 Suppl 1):S6-14. PubMed ID: 24249806
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials.
Wolters PL; Martin S; Merker VL; Tonsgard JH; Solomon SE; Baldwin A; Bergner AL; Walsh K; Thompson HL; Gardner KL; Hingtgen CM; Schorry E; Dudley WN; Franklin B;
Neurology; 2016 Aug; 87(7 Suppl 1):S4-S12. PubMed ID: 27527648
[TBL] [Abstract][Full Text] [Related]
6. Advancing neurofibromatosis and schwannomatosis clinical trial design: Consensus recommendations from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration.
Merker VL; Gross AM; Widemann BC; Plotkin SR
Clin Trials; 2024 Feb; 21(1):3-5. PubMed ID: 37776044
[No Abstract] [Full Text] [Related]
7. Enhancing Neurofibromatosis Clinical Trial Outcome Measures Through Patient Engagement: Lessons From REiNS.
Merker VL; Lessing AJ; Moss I; Hussey M; Oberlander B; Rose T; Thalheimer R; Wirtanen T; Wolters PL; Gross AM; Plotkin SR;
Neurology; 2021 Aug; 97(7 Suppl 1):S4-S14. PubMed ID: 34230208
[TBL] [Abstract][Full Text] [Related]
8. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
9. Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials.
Wolters PL; Vranceanu AM; Thompson HL; Martin S; Merker VL; Baldwin A; Barnett C; Koetsier KS; Hingtgen CM; Funes CJ; Tonsgard JH; Schorry EK; Allen T; Smith T; Franklin B; Reeve S;
Neurology; 2021 Aug; 97(7 Suppl 1):S50-S63. PubMed ID: 34230198
[TBL] [Abstract][Full Text] [Related]
10. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.
Ahlawat S; Fayad LM; Khan MS; Bredella MA; Harris GJ; Evans DG; Farschtschi S; Jacobs MA; Chhabra A; Salamon JM; Wenzel R; Mautner VF; Dombi E; Cai W; Plotkin SR; Blakeley JO; ;
Neurology; 2016 Aug; 87(7 Suppl 1):S31-9. PubMed ID: 27527647
[TBL] [Abstract][Full Text] [Related]
11. Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention.
Walsh KS; Janusz J; Wolters PL; Martin S; Klein-Tasman BP; Toledo-Tamula MA; Thompson HL; Payne JM; Hardy KK; de Blank P; Semerjian C; Gray LS; Solomon SE; Ullrich N;
Neurology; 2016 Aug; 87(7 Suppl 1):S21-30. PubMed ID: 27527646
[TBL] [Abstract][Full Text] [Related]
12. Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1.
Gross AM; Plotkin SR; Watts NB; Fisher MJ; Klesse LJ; Lessing AJ; McManus ML; Larson AN; Oberlander B; Rios JJ; Sarnoff H; Simpson BN; Ullrich NJ; Stevenson DA
Clin Trials; 2024 Feb; 21(1):29-39. PubMed ID: 37772407
[TBL] [Abstract][Full Text] [Related]
13. Patient Report of Hearing in Neurofibromatosis Type 2: Recommendations for Clinical Trials.
Thompson HL; Blanton A; Franklin B; Merker VL; Franck KH; Welling DB;
Neurology; 2021 Aug; 97(7 Suppl 1):S64-S72. PubMed ID: 34230203
[TBL] [Abstract][Full Text] [Related]
14. Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical Trials.
Cannon A; Pichard DC; Wolters PL; Adsit S; Erickson G; Lessing AJ; Li P; Narmore W; Röhl C; Rosser T; Widemann BC; Blakeley JO; Plotkin SR;
Neurology; 2021 Aug; 97(7 Suppl 1):S15-S24. PubMed ID: 34230202
[TBL] [Abstract][Full Text] [Related]
15. Lessons learned from drug trials in neurofibromatosis: A systematic review.
Dhaenens BAE; Ferner RE; Evans DG; Heimann G; Potratz C; van de Ketterij E; Kaindl AM; Hissink G; Carton C; Bakker A; Nievo M; Legius E; Oostenbrink R
Eur J Med Genet; 2021 Sep; 64(9):104281. PubMed ID: 34237445
[TBL] [Abstract][Full Text] [Related]
16. Establishing priorities in neurofibromatosis research: a workshop summary.
MacCollin M; Gutmann DH; Korf B; Finkelstein R
Genet Med; 2001; 3(3):212-7. PubMed ID: 11388764
[TBL] [Abstract][Full Text] [Related]
17. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
Widemann BC; Acosta MT; Ammoun S; Belzberg AJ; Bernards A; Blakeley J; Bretscher A; Cichowski K; Clapp DW; Dombi E; Evans GD; Ferner R; Fernandez-Valle C; Fisher MJ; Giovannini M; Gutmann DH; Hanemann CO; Hennigan R; Huson S; Ingram D; Kissil J; Korf BR; Legius E; Packer RJ; McClatchey AI; McCormick F; North K; Pehrsson M; Plotkin SR; Ramesh V; Ratner N; Schirmer S; Sherman L; Schorry E; Stevenson D; Stewart DR; Ullrich N; Bakker AC; Morrison H
Am J Med Genet A; 2014 Mar; 164A(3):563-78. PubMed ID: 24443315
[TBL] [Abstract][Full Text] [Related]
18. Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis.
Merker VL; Dai A; Radtke HB; Knight P; Jordan JT; Plotkin SR
BMC Health Serv Res; 2018 Aug; 18(1):668. PubMed ID: 30157837
[TBL] [Abstract][Full Text] [Related]
19. Functional outcome measures for NF1-associated optic pathway glioma clinical trials.
Fisher MJ; Avery RA; Allen JC; Ardern-Holmes SL; Bilaniuk LT; Ferner RE; Gutmann DH; Listernick R; Martin S; Ullrich NJ; Liu GT;
Neurology; 2013 Nov; 81(21 Suppl 1):S15-24. PubMed ID: 24249802
[TBL] [Abstract][Full Text] [Related]
20. Neurofibromatosis: part 2--clinical management.
Batista PB; Bertollo EM; Costa Dde S; Eliam L; Cunha KS; Cunha-Melo JR; Darrigo Junior LG; Geller M; Gianordoli-Nascimento IF; Madeira LG; Mendes HM; Miranda DM; Mata-Machado NA; Morato EG; Pavarino ÉC; Pereira LB; Rezende NA; Rodrigues Lde O; Sette JB
Arq Neuropsiquiatr; 2015 Jun; 73(6):531-43. PubMed ID: 26083891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]